This suggests that an increase in PD-L1 mRNA and/or PD-L1 protein levels in EVs during ICI therapy could act as a beneficial biomarker for both the effectiveness and prognosis in advanced NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.